Crescent Biopharma (CBIO) Competitors $12.49 -0.06 (-0.48%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CBIO vs. GERN, ZBIO, RIGL, MYGN, VSTM, EBS, XOMA, LXRX, VNDA, and CDXSShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Geron (GERN), Zenas BioPharma (ZBIO), Rigel Pharmaceuticals (RIGL), Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors Geron Zenas BioPharma Rigel Pharmaceuticals Myriad Genetics Verastem Emergent Biosolutions XOMA Royalty Lexicon Pharmaceuticals Vanda Pharmaceuticals Codexis Crescent Biopharma (NASDAQ:CBIO) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation. Which has better valuation and earnings, CBIO or GERN? Crescent Biopharma has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrescent BiopharmaN/AN/A-$37.88M-$34.93-0.36Geron$76.99M10.52-$174.57M-$0.13-9.77 Is CBIO or GERN more profitable? Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -53.52%. Geron's return on equity of -31.37% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Crescent BiopharmaN/A -106.06% -86.60% Geron -53.52%-31.37%-16.01% Do institutionals & insiders hold more shares of CBIO or GERN? 75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.0% of Crescent Biopharma shares are owned by insiders. Comparatively, 7.4% of Geron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer CBIO or GERN? Crescent Biopharma presently has a consensus target price of $25.60, suggesting a potential upside of 104.96%. Geron has a consensus target price of $3.79, suggesting a potential upside of 198.09%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Geron 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Does the media refer more to CBIO or GERN? In the previous week, Geron had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 5 mentions for Geron and 3 mentions for Crescent Biopharma. Geron's average media sentiment score of 1.70 beat Crescent Biopharma's score of 0.68 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, CBIO or GERN? Crescent Biopharma has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. SummaryCrescent Biopharma and Geron tied by winning 8 of the 16 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.35M$2.59B$5.84B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-0.3623.8575.4125.98Price / SalesN/A529.66515.81181.13Price / CashN/A171.1637.5660.44Price / Book1.525.3712.156.29Net Income-$37.88M$32.95M$3.29B$271.07M7 Day Performance-12.29%1.28%0.74%3.87%1 Month Performance-10.14%6.09%4.81%4.88%1 Year PerformanceN/A-2.15%60.57%26.12% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma4.3849 of 5 stars$12.49-0.5%$25.60+105.0%N/A$245.35MN/A-0.3650GERNGeron3.1304 of 5 stars$1.48+5.4%$4.19+183.9%-71.5%$941.08M$76.99M-11.35229Positive NewsZBIOZenas BioPharma1.0637 of 5 stars$17.62+10.1%$36.67+108.1%N/A$741.98M$5M-4.96N/ARIGLRigel Pharmaceuticals2.0437 of 5 stars$38.52-0.9%$38.20-0.8%+193.1%$690.96M$179.28M7.12160News CoveragePositive NewsShort Interest ↓MYGNMyriad Genetics3.7176 of 5 stars$6.98+9.5%$12.45+78.6%-72.6%$651.75M$837.60M-1.642,700Positive NewsVSTMVerastem2.7355 of 5 stars$9.27+0.2%$13.29+43.4%+250.9%$569.92M$10K-2.8250News CoverageAnalyst ForecastGap DownEBSEmergent Biosolutions4.7499 of 5 stars$8.32+0.2%$14.33+72.3%+7.1%$444.67M$1.04B3.402,420XOMAXOMA Royalty4.2024 of 5 stars$34.68+6.8%$69.50+100.4%+34.7%$414.50M$12.77M-22.1210Positive NewsAnalyst UpgradeLXRXLexicon Pharmaceuticals2.2012 of 5 stars$1.12+1.4%$3.23+189.2%-31.1%$405.19M$31.08M-3.38140News CoverageVNDAVanda Pharmaceuticals4.1836 of 5 stars$4.73-0.1%$16.50+249.2%-9.6%$279.20M$198.77M-4.18290Positive NewsCDXSCodexis3.3874 of 5 stars$2.52-7.8%$11.00+337.0%-11.0%$227.93M$59.35M-3.04250Positive News Related Companies and Tools Related Companies Geron Competitors Zenas BioPharma Competitors Rigel Pharmaceuticals Competitors Myriad Genetics Competitors Verastem Competitors Emergent Biosolutions Competitors XOMA Royalty Competitors Lexicon Pharmaceuticals Competitors Vanda Pharmaceuticals Competitors Codexis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CBIO Stock Alerts